Sarasota, Fla., USA - August 7, 2014, Sarasota, Fla., USA - Rock Creek Pharmaceuticals, Inc., an emerging drug development company, announced the election of Lee M. Canaan and Edward J. McDonnell as new directors.
Article continues below
Ms. Canaan brings twenty-five years of financial and public capital markets experience and thirty-five years of scientific and technical expertise to our board. She has working knowledge of both debt and equity markets as an institutional investor and a corporate finance professional and has served on the board of several publicly-traded companies. Currently Ms. Canaan is the portfolio manager of a private money management firm she founded in 2003.
Prior to that, she was a fixed income analyst for the high yield debt team at AIM Management (part of the Invesco Family of funds) after making the transition from corporate finance professional in the treasury operations of ARCO, a Fortune 100 energy company.
Ms. Canaan started her career as a geophysicist at AMOCO. She also has private market investment experience and was recognized by the U.S. Department of Energy as a financial and technical expert for the purposes of evaluating government investments in the renewable energy space.
Ms. Canaan has a B.S. in Geological Sciences from the University of Southern California, a Masters in Geophysics from the University of Texas at Austin, and an M.B.A. in Finance from the Wharton School at the University of Pennsylvania. She holds the Chartered Financial Analyst (CFA) designation. Ms. Canaan resides in Ann Arbor, MI.
Mr. McDonnell, MPH has a long, distinguished career in both the private, public and government sector. Most recently, Mr. McDonnell serves as President at Compliance Management Consulting, an independent consulting service, that provides expert advice, regulatory vulnerability assessments and compliance management know how to FDA regulated industries since 2000.
Previously, Mr. McDonnell spent 5 years at Quintiles Consulting and Quintiles Quality Regulatory Alliance, (formerly BRI Quality Regulatory Alliance, where he was President and Chief Operating Officer), providing expert quality and regulatory services to the biomedical industry. Throughout this time he managed oversight of products, services, contracts, internal procedures, including U.S., European, and Pacific Rim requirements for GLP, GCP, GMP regulations and ISO 9000/Quality Systems Standards.
Mr. McDonnell's government experience includes a twenty eight year career with the Federal Drug Administration (FDA). He spent the last seven years of his FDA career as Director of the New England District Office, where he provided executive direction to consumer protection and enforcement programs throughout the New England States and earned the FDA Award of merit for precedent enforcement actions.
During his ten years as Director, Division of Compliance Programs at the FDA's, Center for Devices and Radiological Health, he was responsible for the development and application of Good Manufacturing Regulations (GMPs) for the manufacture of medical devices and for the implementation of new medical device legislation.
Mr. McDonnell started his FDA career as a Food and Drug Inspector in the Boston District Office specializing in the inspection of drug and device manufacturers. At the conclusion of his FDA career he was awarded the FDA Distinguished Career Service Award. ■